{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:30:52Z","timestamp":1776792652797,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/objective<\/jats:title>\n                <jats:p>Intra-operative radiation therapy (IORT) is a newer partial breast irradiation technique that has been well studied in 2 large randomized trials, the TARGIT-A and ELIOT trials. We initiated our IORT program in 2018 in the context of a registry trial, and aim to report our early results thus far.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We instituted an IORT practice using Intrabeam\u00ae low energy 50kVp x-rays for selected breast cancer cases in 2018. Patients were enrolled on our institutional registry protocol which allowed for IORT in ER\u2009+\u2009patients with grade 1\u20132 DCIS\u2009\u2264\u20092.5\u00a0cm or invasive disease\u2009\u2264\u20093.5\u00a0cm in patients of at least 45 years of age.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between January 2018 and December 2021, 181 patients with clinical stage 0-IIA ER\u2009+\u2009breast cancer were evaluated. One hundred sixty-seven patients ultimately received IORT to 172 sites. The majority of patients received IORT at the time of initial diagnosis and surgery (160\/167; 95.8%). Re-excision post IORT occurred in 16\/167 patients (9.6%) due to positive margins. Adjuvant RT to the whole breast +\/- LN was ultimately given to 23\/167 (13.8%) patients mainly due to positive sentinel LN found on final pathology (12\/23; 52%); other reasons were close margins for DCIS (3\/23; 13%), tumor size (3\/23; 4.3%), and multifactorial (5\/23; 17.4%). Five patients (3%) had post-operative complications of wound dehiscence. There were 3 local recurrences (1.6%) at a median follow-up of 27.9 months (range: 0.7\u2013 54.8 months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IORT has been proven to be a safe and patient-centered form of local adjuvant RT for our population, in whom compliance with a longer course of external beam radiation can be an issue. Long term efficacy remains to be evaluated through continued follow up. In the era of COVID-19 and beyond, IORT has been an increasingly attractive option, as it greatly minimizes toxicities and patient visits to the clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>All patients were prospectively enrolled on an institutional review board-approved registry trial (IRB number: 2018\u20139409).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02299-0","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T11:01:53Z","timestamp":1690282913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Experience with intraoperative radiation therapy in an urban cancer center"],"prefix":"10.1186","volume":"18","author":[{"given":"Therese Youssef","family":"Andraos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin A.","family":"Skalina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang A.","family":"Tome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjuli M.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana L.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"issue":"9503","key":"2299_CR1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087\u2013106.","journal-title":"Lancet"},{"issue":"1","key":"2299_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","volume":"16","author":"H Bartelink","year":"2015","unstructured":"Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47\u201356.","journal-title":"Lancet Oncol"},{"key":"2299_CR3","unstructured":"Surgeons TASoB. Consensus Guidelines on Accelerated Partial Breast Irradiation2018."},{"issue":"4","key":"2299_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.brachy.2013.02.001","volume":"12","author":"C Shah","year":"2013","unstructured":"Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The american Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2013;12(4):267\u201377.","journal-title":"Brachytherapy"},{"issue":"1","key":"2299_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.brachy.2017.09.004","volume":"17","author":"C Shah","year":"2018","unstructured":"Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, et al. The american Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17(1):154\u201370.","journal-title":"Brachytherapy"},{"issue":"10215","key":"2299_CR6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)32514-0","volume":"394","author":"FA Vicini","year":"2019","unstructured":"Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155\u201364.","journal-title":"Lancet"},{"issue":"5","key":"2299_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(21)00080-2","volume":"22","author":"R Orecchia","year":"2021","unstructured":"Orecchia R, Veronesi U, Maisonneuve P, Galimberti VE, Lazzari R, Veronesi P, et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021;22(5):597\u2013608.","journal-title":"Lancet Oncol"},{"issue":"13","key":"2299_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(13)70497-2","volume":"14","author":"U Veronesi","year":"2013","unstructured":"Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269\u201377.","journal-title":"Lancet Oncol"},{"issue":"2S","key":"2299_CR9","first-page":"38","volume":"115","author":"AL Burnett","year":"2023","unstructured":"Burnett AL, Nyame YA, Mitchell E. Disparities in prostate cancer. J Natl Med Assoc. 2023;115(2S):38\u2013S45.","journal-title":"J Natl Med Assoc"},{"key":"2299_CR10","doi-asserted-by":"crossref","unstructured":"Kantor O, King TA, Freedman RA, Mayer EL, Chavez-MacGregor M, Korde LA et al. Racial and ethnic disparities in Locoregional recurrence among patients with hormone Receptor-Positive, node-negative breast Cancer: a Post Hoc Analysis of the TAILORx Randomized Clinical Trial. JAMA Surg. 2023.","DOI":"10.1001\/jamasurg.2023.0297"},{"issue":"7","key":"2299_CR11","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1245\/s10434-020-08450-5","volume":"27","author":"SA Valente","year":"2020","unstructured":"Valente SA, Shah C. The Landmark Series: Adjuvant Radiation therapy for breast Cancer. Ann Surg Oncol. 2020;27(7):2203\u201311.","journal-title":"Ann Surg Oncol"},{"key":"2299_CR12","doi-asserted-by":"publisher","first-page":"m2836","DOI":"10.1136\/bmj.m2836","volume":"370","author":"JS Vaidya","year":"2020","unstructured":"Vaidya JS, Bulsara M, Baum M, Wenz F, Massarut S, Pigorsch S, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ. 2020;370:m2836.","journal-title":"BMJ"},{"issue":"3","key":"2299_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41416-021-01440-8","volume":"125","author":"JS Vaidya","year":"2021","unstructured":"Vaidya JS, Bulsara M, Baum M, Wenz F, Massarut S, Pigorsch S, et al. New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. Br J Cancer. 2021;125(3):380\u20139.","journal-title":"Br J Cancer"},{"issue":"7","key":"2299_CR14","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1470-2045(21)00278-3","volume":"22","author":"JS Vaidya","year":"2021","unstructured":"Vaidya JS, Bulsara M, Massarut S, Sperk E, Wenz F, Tobias JS, et al. Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial. Lancet Oncol. 2021;22(7):e295\u2013e6.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2299_CR15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa040587","volume":"351","author":"KS Hughes","year":"2004","unstructured":"Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971\u20137.","journal-title":"N Engl J Med"},{"key":"2299_CR16","doi-asserted-by":"crossref","unstructured":"Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. investigators PI. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266 \u2013 73.","DOI":"10.1016\/S1470-2045(14)71221-5"},{"issue":"7","key":"2299_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2207586","volume":"388","author":"IH Kunkler","year":"2023","unstructured":"Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in early breast Cancer. N Engl J Med. 2023;388(7):585\u201394.","journal-title":"N Engl J Med"},{"key":"2299_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1471-2407-12-171","volume":"12","author":"C Neumaier","year":"2012","unstructured":"Neumaier C, Elena S, Grit W, Yasser AM, Uta KT, Anke K, et al. TARGIT-E(lderly)--prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. BMC Cancer. 2012;12:171.","journal-title":"BMC Cancer"},{"issue":"1","key":"2299_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/tbj.12516","volume":"22","author":"R Rivera","year":"2016","unstructured":"Rivera R, Banks A, Casillas-Lopez A, Rashtian A, Lewinsky B, Sheth P, et al. Targeted intraoperative Radiotherapy for the management of Ductal Carcinoma in situ of the breast. Breast J. 2016;22(1):63\u201374.","journal-title":"Breast J"},{"key":"2299_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.17161\/kjm.vol1415147","volume":"14","author":"J Leatherman","year":"2021","unstructured":"Leatherman J, Nicholas C, Cusick T, Cooke E, Ablah E, Okut H, et al. Intra-operative Radiation Therapy versus whole breast External Beam Radiotherapy: a comparison of patient-reported outcomes. Kans J Med. 2021;14:170\u20135.","journal-title":"Kans J Med"},{"issue":"9","key":"2299_CR21","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1245\/s10434-013-2997-3","volume":"20","author":"MD Alvarado","year":"2013","unstructured":"Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, et al. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013;20(9):2873\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2299_CR22","doi-asserted-by":"publisher","first-page":"e014944","DOI":"10.1136\/bmjopen-2016-014944","volume":"7","author":"A Vaidya","year":"2017","unstructured":"Vaidya A, Vaidya P, Both B, Brew-Graves C, Bulsara M, Vaidya JS. Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open. 2017;7(8):e014944.","journal-title":"BMJ Open"},{"issue":"3","key":"2299_CR23","doi-asserted-by":"publisher","first-page":"101141","DOI":"10.1016\/j.adro.2022.101141","volume":"8","author":"JM Jiang","year":"2023","unstructured":"Jiang JM, Eichler J, Bodner W, Fox J, Garg M, Kabarriti R, et al. Predictors of Financial Toxicity in Patients receiving Concurrent Radiation Therapy and Chemotherapy. Adv Radiat Oncol. 2023;8(3):101141.","journal-title":"Adv Radiat Oncol"},{"issue":"15","key":"2299_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2217\/fon-2018-0874","volume":"15","author":"J Klein","year":"2019","unstructured":"Klein J, Bodner W, Garg M, Kalnicki S, Ohri N. Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. Future Oncol. 2019;15(15):1697\u2013705.","journal-title":"Future Oncol"},{"issue":"4","key":"2299_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00066-019-01525-7","volume":"196","author":"M Pez","year":"2020","unstructured":"Pez M, Keller A, Welzel G, Abo-Madyan Y, Ehmann M, Tuschy B, et al. Long-term outcome after intraoperative radiotherapy as a boost in breast cancer. Strahlenther Onkol. 2020;196(4):349\u201355.","journal-title":"Strahlenther Onkol"},{"key":"2299_CR26","doi-asserted-by":"publisher","first-page":"850351","DOI":"10.3389\/fonc.2022.850351","volume":"12","author":"GR Sarria","year":"2022","unstructured":"Sarria GR, Ramos ML, Palacios A, Del Castillo R, Castro F, Calvo A, et al. Long-term outcomes of an International Cooperative Study of Intraoperative Radiotherapy Upfront Boost with Low Energy X-Rays in breast Cancer. Front Oncol. 2022;12:850351.","journal-title":"Front Oncol"},{"issue":"1","key":"2299_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13014-016-0749-9","volume":"12","author":"F Sedlmayer","year":"2017","unstructured":"Sedlmayer F, Reitsamer R, Wenz F, Sperk E, Fussl C, Kaiser J, et al. Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol. 2017;12(1):23.","journal-title":"Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02299-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T11:02:43Z","timestamp":1690282963000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02299-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02299-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Prior to treatment, all patients were prospectively enrolled and consent to participate in an institutional review board-approved registry trial (IRB number: 2018\u20139409).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"123"}}